Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results
(NASDAQ:QNRX), – Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation Awarded by FDA to QRX003 for Netherton Syndrome – Pediatric Netherton Clinical Program Expanded Based on Positive Long-Term Safety and Efficacy […]